Sonoma Pharmaceuticals, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Sonoma Pharmaceuticals shows concerning financial deterioration with cash declining 52% to $2.6M, continuing operating losses of $2.1M, and a substantial $5.5M withholding tax liability creating significant liquidity pressure. Despite 33% revenue growth, the company faces potential going concern issues given current burn rate.
Red Flags Detected (5)
Cash declined 52% from $5.4M to $2.6M in 9 months
Large $5.5M withholding tax payable represents 40% of total assets
Current liquidity of $2.6M cash vs ongoing quarterly operating losses of ~$678K
2 more red flags detected
Key Takeaways
Revenue growth of 33% to $14M demonstrates market traction but insufficient to offset losses
Gross margin improved to 37.5% vs 37.4% prior year showing modest operational efficiency
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.